Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

To compare stability of wound healing after manual SICS vs phacoemulsification surgery

Search Title by author or title

Session Details

Session Title: Orbis Free Paper Session

Session Date/Time: Monday 12/09/2016 | 11:30-12:45

Paper Time: 11:42

Venue: Room B10

First Author: : R.Deshpande INDIA

Co Author(s): :    K. Dole                    

Abstract Details

Purpose:

To know how many post-operative follow ups are needed and when can spectacles be prescribed after manual SICS versus phacoemulsification surgery.

Setting:

A tertiary eye care centre in Western India.

Methods:

This prospective randomized unmasked interventional clinical trial was conducted in 310 patients. The patients were seen on post-operative day 1, 7 and 30 for assessing anatomical and functional stability using parameters like keratometry values and uncorrected visual acuity (UCVA).

Results:

There were 150 patients in each group. The mean vertical curvature of cornea in the SICS group was 43.62, 43.56 and 43.60 whereas it was 44.02, 43.95 and 43.91 in the phacoemulsification group at day 1, 7 and 30. In both groups, there was no significant over course of time. There was no significant change in astigmatism in both the groups at day 1,7 and 30.The pecentage of patients with UCVA better than 6/18 was 66.44, 72.25 and 79.34 in SICS group while it was 78.71, 90.96 and 96.12 in the phacoemulsification group at day 1,7 and 30 respectively.

Conclusions:

The result of our study showed that stability of wound healing after manual sics was better as compared to phacoemulsification. As there was no significant change in mean corneal astigmatism and UCVA after SICS on day 7 and day 30 we can suggest only 2 follow ups for the patient and can prescribe spectacles on day 7. this will reduce the economic burden on the patients without compromising the outcome.

Financial Disclosure:

NONE

Back to previous